NCT07439991 Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
| NCT ID | NCT07439991 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Hospital of Jilin University |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2029-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2024-11-01 with a primary completion date of 2029-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is: Which clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk? Participants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Patients undergoing surgical resection for lung cancer 3. Postoperative hospital stay ≥ 48 hours 4. Availability of perioperative clinical, laboratory, and imaging data 5. Willingness to provide informed consent and participate in 30-day follow-up Exclusion Criteria: 1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery 2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks 3. Severe coagulation disorders or bleeding diseases 4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection 5. Concurrent major organ surgery (e.g., cardiac, liver surgery) 6. Pregnancy or lactation 7. Incomplete postoperative follow-up data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07439991 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07439991 currently recruiting?
Yes, NCT07439991 is actively recruiting participants. Contact the research team at l_w01@jlu.edu.cn for enrollment information.
Where is the NCT07439991 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT07439991 clinical trial?
NCT07439991 is sponsored by The First Hospital of Jilin University. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.